<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39254458</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>312</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Radiology</Title><ISOAbbreviation>Radiology</ISOAbbreviation></Journal><ArticleTitle>Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease.</ArticleTitle><Pagination><StartPage>e233094</StartPage><MedlinePgn>e233094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e233094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.233094</ELocationID><Abstract><AbstractText>Background US shear-wave elastography (SWE) and vibration-controlled transient elastography (VCTE) enable assessment of liver stiffness, an indicator of fibrosis severity. However, limited reproducibility data restrict their use in clinical trials. Purpose To estimate SWE and VCTE measurement variability in nonalcoholic fatty liver disease (NAFLD) within and across systems to support clinical trial diagnostic enrichment and clinical interpretation of longitudinal liver stiffness. Materials and Methods This prospective, observational, cross-sectional study (March 2021 to November 2021) enrolled adults with NAFLD, stratified according to the Fibrosis-4 (FIB-4) index (≤1.3, &gt;1.3 and &lt;2.67, ≥2.67), at two sites to assess SWE with five US systems and VCTE with one system. Each participant underwent 12 elastography examinations over two separate days within 1 week, with each day's examinations conducted by a different operator. VCTE and SWE measurements were reported in units of meters per second. The primary end point was the different-day, different-operator reproducibility coefficient (RDC<sub>DDDO</sub>) pooled across systems for SWE and individually for VCTE. Secondary end points included system-specific RDC<sub>DDDO</sub>, same-day, same-operator repeatability coefficient (RC<sub>SDSO</sub>), and between-system same-day, same-operator reproducibility coefficient. The planned sample provided 80% power to detect a pooled RDC<sub>DDDO</sub> of less than 35%, the prespecified performance threshold. Results A total of 40 participants (mean age, 60 years ± 10 [SD]; 24 women) with low (<i>n</i> = 17), intermediate (<i>n</i> = 15), and high (<i>n</i> = 8) FIB-4 scores were enrolled. RDC<sub>DDDO</sub> was 30.7% (95% upper bound, 34.4%) for SWE and 35.6% (95% upper bound, 43.9%) for VCTE. SWE system-specific RDC<sub>DDDO</sub> varied from 24.2% to 34.3%. The RC<sub>SDSO</sub> was 21.0% for SWE (range, 13.9%-35.0%) and 19.6% for VCTE. The SWE between-system same-day, same-operator reproducibility coefficient was 52.7%. Conclusion SWE met the prespecified threshold, RDC<sub>DDDO</sub> less than 35%, with VCTE having a higher RDC<sub>DDDO</sub>. SWE variability was higher between different systems. These estimates advance liver US-based noninvasive test qualification by <i>(a)</i> defining expected variability, <i>(b)</i> establishing that serial examination variability is lower when performed with the same system, and <i>(c)</i> informing clinical trial design. ClinicalTrials.gov Identifier NCT04828551 © RSNA, 2024 <i>Supplemental material is available for this article.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pierce</LastName><ForeName>Theodore T</ForeName><Initials>TT</Initials><Identifier Source="ORCID">0000-0003-3244-0994</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ozturk</LastName><ForeName>Arinc</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5335-3737</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherlock</LastName><ForeName>Sarah P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0001-5351-3828</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura Cunha</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6403-5155</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0924-9892</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8827-939X</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0004-3595-9884</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Marian</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2845-2725</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corey</LastName><ForeName>Kathleen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edenbaum</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3214-6787</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Sudha S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heymann</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0003-9855-5054</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamphaus</LastName><ForeName>Tania N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calle</LastName><ForeName>Roberto A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-6577-5657</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Covarrubias</LastName><ForeName>Yesenia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loomba</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4845-9991</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obuchowski</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0003-1891-7477</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanyal</LastName><ForeName>Arun J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-8682-5748</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirlin</LastName><ForeName>Claude B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0002-6639-9072</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fowler</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0001-9188-1701</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Samir</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-7801-8724</Identifier><AffiliationInfo><Affiliation>From the Center for Ultrasound Research and Translation, Massachusetts General Hospital, 55 Fruit St, White Bldg, Rm 270, Boston, MA 02114 (T.T.P., A.O., X.W., Q.L., D.H., M.M., H.E., A.E.S.); Harvard Medical School, Boston, Mass (T.T.P., A.O., Q.L., A.E.S.); Pfizer, Cambridge, Mass (S.P.S.); Department of Radiology, University of Washington, Seattle, Wash (G.M.C.); Department of Ultrasound, Shenzhen University General Hospital, Shenzhen, China (Q.L.); Department of Radiology, Liver Imaging Group, University of California San Diego, La Jolla, Calif (M.S.M., Y.C., C.B.S., K.J.F.); MGH Fatty Liver Program, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass (K.E.C.); BioAge Labs, Richmond, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (H.H., T.N.K.); Regeneron Pharmaceuticals, Tarrytown, NY (R.A.C.); Department of Medicine, Division of Gastroenterology, NAFLD Research Center, University of California at San Diego, La Jolla, Calif (R.L.); Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.A.O.); and Department of Internal Medicine, Division of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond, Va (A.J.S.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04828551</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Radiology</MedlineTA><NlmUniqueID>0401260</NlmUniqueID><ISSNLinking>0033-8419</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054459" MajorTopicYN="Y">Elasticity Imaging Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosures of conflicts of interest: </b><b>T.T.P.</b> Grants paid through institution from U.S. Department of
Defense, GE, National Institutes of Health, Food and Drug Administration,
Society of Abdominal Radiology, and American Roentgen Ray Society; honoraria
for prior talks from Massachusetts Society of Radiologic Technologists and
Zhejiang Medical Association; equity and consultant for AutonomUS Medical
Technologies; royalties from Elsevier. <b>A.O.</b> Consulting fees
from Novo Nordisk SmartAlpha, and AutonomUS; Euroson conference attendance
supported by conference organizers. <b>S.P.S.</b> Employee of Pfizer
and AstraZeneca; owner of restricted stock units and stock options in
Pfizer. <b>G.M.C.</b> No relevant relationships. <b>X.W.</b> No
relevant relationships. <b>Q.L.</b> No relevant relationships.
<b>D.H.</b> No relevant relationships. <b>M.S.M.</b>
Laboratory service agreements or grants under UCSD from Alexion, Celgene,
Enanta, GE, Intercept, Pfizer, Roche, and Shire; consulting fees from
Alimentive, Arrowhead, AutonomUS, Glympse, Kowa, Livivos, Median, Novo
Nordisk, and PharmaNest; travel expenses from the Liver Forum, NASH CRN, and
Liver Cirrhosis Network; steering committee member and chair of the
Radiology Disease Program for The Liver Forum; steering Committee of NASH
CRN; co-founder of QuantixBio; stock in Pfizer; stock options in QuantixBio
and AutonomUS; stock options pending for Livivos; grant advising for
AutonomUS and grant writing for PharmaNest. <b>M.M.</b> No relevant
relationships. <b>K.E.C.</b> Consulting fees from Medscape,
Theratechnologies, and Sagimet. <b>H.E.</b> No relevant relationships.
<b>S.S.S.</b> No relevant relationships. <b>H.H.</b> No
relevant relationships. <b>T.N.K.</b> No relevant relationships.
<b>R.A.C.</b> Stock or stock options in Regeneron Pharmaceuticals
and Pfizer. <b>Y.C.</b> No relevant relationships. <b>R.L.</b>
Grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim,
Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept,
Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals,
Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals;
consulting fees from Aardvark Therapeutics, Altimmune, Arrowhead
Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead,
Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio,
Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda,
Terns Pharmaceuticals and Viking Therapeutics; stock options in Sagimet
Biosciences; co-founder of LipoNexus. <b>N.A.O.</b> Contract between
fNIH and Cleveland Clinic for statistical consulting. <b>A.J.S.</b>
Grants to institution from Gilead, Eli Lilly, Novo Nordisk, Pfizer, Bristol
Myers Squibb, Intercept, Merck, Salix, Echosense, Hanmi, Madrigal;
consulting fees from Merck, Novo Nordisk, Eli Lilly, Pfizer, Genentech,
Amgen, Alnylam, Regeneron, Poxel, Tern, Akero, 89Bio, Altimmune, Northsea,
Histoindex, Path AI, Aligos, Surrozen, Zydus, Sun Pharma, Myovant, Salix;
honoraria for lectures at educational CME events from Merck and Novo
Nordisk; patent to institution for DIAMOND model of mouse; participation on
a DataSafety Monitoring Board or Advisory Board for Sequana and Bard; stock
options in Genfit, Tiziana, Durect, Exhalenz, Rivus, Northsea, and
Inversago. <b>C.B.S.</b> Grants to institution from ACR, Bayer, GE,
Pfizer, Gilead, Philips, Siemens, V Foundation, OrsoBio, Enanta, Gilead,
ICON, Intercept, Nusirt, Shire, Synageva, Takeda; royalties or licenses from
Medscape and Wolters Kluwer; personal consulting fees (payments or
stock/stock options) from Altimmune, Ascelia Pharma, Blade, Boehringer,
Epigenomics, Guerbet, and Livivos; institutional consulting fees from AMRA,
Exact Sciences, and Pfizer; payments for educational symposia; support for
attending meetings and/or travel from Fundacion Santa Fe, Congreso Argentino
de Diagnóstico por Imágenes, Stanford, Jornada Paulista de
Radiologia, Ascelia Pharma, and University of Cincinnati; participation
(unpaid) on a Data Safety and Monitoring Board for National Cancer
Institute–funded Early Detection Research Network; executive position
for Livivos (Chief Medical Officer, unsalaried position with stock options
and stock) through June 28, 2023; principal Scientific Advisor to Livivos
(unsalaried position with stock options and stock) since June 28, 2023;
stock and stock options in Livivos; equipment loans (contrast material) from
GE, Siemens, and Bayer; payment to institution for academic co-chair,
Imaging Workstream, NIMBLE. <b>K.J.F.</b> Grants from GE, Bayer,
Siemens, Pfizer, and Median; consulting fees from Ascelia, Guerbet, and
Bayer; payment or honoraria from vrad for CME science; payment for expert
witness testimony; support for attending meetings and/or travel from Bayer;
leadership or fiduciary role in other board, society, committee, or advocacy
group for ACR, RSNA, and SAR; senior deputy editor of
<i>Radiology</i>. <b>A.E.S.</b> Consultant for numerous
healthcare organizations, which, in the past 2 years, include General
Electric, Resolve Stroke, Cryosa, Ochre Bio, Rhino Healthtech, and Gerson
Lehman Group; member of advisory or scientific boards for General Electric,
Rhino Healthtech, Ochre Bio, Resolve Stroke, and FNIH; has received research
support from Canon, Echosens, General Electric HealthCare, Philips, Siemens,
and Supersonic Imagine/Hologic; has received research funding from Analogic,
the U.S. Department of Defense, Fujifilm Healthcare, FNIH, NIH, and General
Electric HealthCare; holds stock options or equity in AutonomUS Medical
Technologies, Evidence Based Psychology, Klea, Katharos Labs, Quantix Bio,
Rhino Healthtech, Ochre Bio, and Resolve Stroke.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39254458</ArticleId><ArticleId IdType="pmc">PMC11427856</ArticleId><ArticleId IdType="doi">10.1148/radiol.233094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Younossi ZM . Non-alcoholic fatty liver disease - A global public health perspective . J Hepatol 2019. ; 70 ( 3 ): 531 – 544 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM , Loomba R , Rinella ME , et al. . Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis . Hepatology 2018. ; 68 ( 1 ): 361 – 371 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508084</ArticleId><ArticleId IdType="pubmed">29222911</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M , Loomis AK , Fairburn-Beech J , et al. . Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease . BMC Med 2018. ; 16 ( 1 ): 130 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088429</ArticleId><ArticleId IdType="pubmed">30099968</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel K , Sebastiani G . Limitations of non-invasive tests for assessment of liver fibrosis . JHEP Rep 2020. ; 2 ( 2 ): 100067 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047178</ArticleId><ArticleId IdType="pubmed">32118201</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal AJ , Shankar SS , Calle RA , et al. . Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project . Nat Med 2022. ; 28 ( 3 ): 430 – 432 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9588405</ArticleId><ArticleId IdType="pubmed">35145308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce TT , Samir AE . Liver Fibrosis: Point-Ultrasound Elastography Is a Safe, Widely Available, Low-Cost, Noninvasive Biomarker of Liver Fibrosis That Is Suitable for Broad Community Use . AJR Am J Roentgenol 2022. ; 219 ( 3 ): 382 – 383 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9608361</ArticleId><ArticleId IdType="pubmed">35319907</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Shea A , Pierce TT . US Elastography in Hepatic Fibrosis-Radiology In Training . Radiology 2021. ; 299 ( 2 ): 264 – 271 .</Citation><ArticleIdList><ArticleId IdType="pubmed">33754829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler LG , Barnhart HX , Buckler AJ , et al. ; QIBA Terminology Working Group . The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions . Stat Methods Med Res 2015. ; 24 ( 1 ): 9 – 26 .</Citation><ArticleIdList><ArticleId IdType="pubmed">24919826</ArticleId></ArticleIdList></Reference><Reference><Citation>
QIBA Profile: Ultrasound
Measurement of Shear Wave Speed for Estimation of Liver
Fibrosis
. 
Quantitative Biomarkers
Alliance
. 
https://qibawiki.rsna.org/images/b/b7/QIBA_US_SWS_Profile_10.21.19.pdf.
Published October 21, 2019. Accessed August
3,2020
.
</Citation></Reference><Reference><Citation>Grundy SM , Cleeman JI , Daniels SR , et al. ; National Heart, Lung, and Blood Institute . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement . Circulation 2005. ; 112 ( 17 ): 2735 – 2752 . [Published corrections appear in Circulation 2005;112(17):e297 and Circulation 2005;112(17):e298.]</Citation><ArticleIdList><ArticleId IdType="pubmed">16157765</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling RK , Lissen E , Clumeck N , et al. ; APRICOT Clinical Investigators . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection . Hepatology 2006. ; 43 ( 6 ): 1317 – 1325 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16729309</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella ME , Neuschwander-Tetri BA , Siddiqui MS , et al. . AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease . Hepatology 2023. ; 77 ( 5 ): 1797 – 1835 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10735173</ArticleId><ArticleId IdType="pubmed">36727674</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AG , Lydecker A , Murray K , Tetri BN , Contos MJ , Sanyal AJ ; Nash Clinical Research Network . Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease . Clin Gastroenterol Hepatol 2009. ; 7 ( 10 ): 1104 – 1112 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079239</ArticleId><ArticleId IdType="pubmed">19523535</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal AJ , Munoz B , Cusi K , et al. ; TARGET-NASH Investigators . Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort . Clin Gastroenterol Hepatol 2023. ; 21 ( 11 ): 2889 – 2900.e10 .</Citation><ArticleIdList><ArticleId IdType="pubmed">36871772</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders JB , Aasland OG , Babor TF , de la Fuente JR , Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II . Addiction 1993. ; 88 ( 6 ): 791 – 804 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8329970</ArticleId></ArticleIdList></Reference><Reference><Citation>Raunig DL , McShane LM , Pennello G , et al. ; QIBA Technical Performance Working Group . Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment . Stat Methods Med Res 2015. ; 24 ( 1 ): 27 – 67 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574197</ArticleId><ArticleId IdType="pubmed">24919831</ArticleId></ArticleIdList></Reference><Reference><Citation>Obuchowski NA , Barnhart HX , Buckler AJ , et al. ; Case Example Working Group . Statistical issues in the comparison of quantitative imaging biomarker algorithms using pulmonary nodule volume as an example . Stat Methods Med Res 2015. ; 24 ( 1 ): 107 – 140 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263699</ArticleId><ArticleId IdType="pubmed">24919828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto R , Suga M , Usumura M , et al. . Shear wave speed measurement bias in a viscoelastic phantom across six ultrasound elastography systems: a comparative study with transient elastography and magnetic resonance elastography . J Med Ultrason 2022. ; 49 ( 2 ): 143 – 152 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038798</ArticleId><ArticleId IdType="pubmed">35061118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler KJ , Venkatesh SK , Obuchowski N , et al. . Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium . Radiology 2023. ; 309 ( 1 ): e231092 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10625902</ArticleId><ArticleId IdType="pubmed">37815451</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddowes PJ , Sasso M , Allison M , et al. . Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease . Gastroenterology 2019. ; 156 ( 6 ): 1717 – 1730 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30689971</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui MS , Vuppalanchi R , Van Natta ML , et al. ; NASH Clinical Research Network . Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease . Clin Gastroenterol Hepatol 2019. ; 17 ( 1 ): 156 – 163.e2 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203668</ArticleId><ArticleId IdType="pubmed">29705261</ArticleId></ArticleIdList></Reference><Reference><Citation>Castera L , Friedrich-Rust M , Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease . Gastroenterology 2019. ; 156 ( 5 ): 1264 – 1281.e4 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505052</ArticleId><ArticleId IdType="pubmed">30660725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BK , Fung J , Yuen MF , Kim SU . Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives . World J Gastroenterol 2013. ; 19 ( 12 ): 1890 – 1900 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613104</ArticleId><ArticleId IdType="pubmed">23569334</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsome PN , Buchholtz K , Cusi K , et al. ; NN9931-4296 Investigators . A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis . N Engl J Med 2021. ; 384 ( 12 ): 1113 - 1124 .</Citation><ArticleIdList><ArticleId IdType="pubmed">33185364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuppalanchi R , Siddiqui MS , Van Natta ML , et al. ; NASH Clinical Research Network . Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease . Hepatology 2018. ; 67 ( 1 ): 134 – 144 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5739967</ArticleId><ArticleId IdType="pubmed">28859228</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraquelli M , Rigamonti C , Casazza G , et al. . Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease . Gut 2007. ; 56 ( 7 ): 968 – 973 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994385</ArticleId><ArticleId IdType="pubmed">17255218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiha GE , El-Etreby S , Bahgat M , et al. . Chronic Hepatitis C Patients with Obesity: Do we Need two Operators for Accurate Evaluation of Liver Stiffness? Ann Hepatol 2018. ; 17 ( 5 ): 795 – 801 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30145567</ArticleId></ArticleIdList></Reference><Reference><Citation>Perazzo H , Fernandes FF , Gomes A , Terra C , Perez RM , Figueiredo FA . Interobserver variability in transient elastography analysis of patients with chronic hepatitis C . Liver Int 2015. ; 35 ( 5 ): 1533 – 1539 .</Citation><ArticleIdList><ArticleId IdType="pubmed">24684234</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca B , Resino E , Torres V , Herrero E , Penades M . Interobserver discrepancy in liver fibrosis using transient elastography . J Viral Hepat 2012. ; 19 ( 10 ): 711 – 715 .</Citation><ArticleIdList><ArticleId IdType="pubmed">22967102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimbeni F , Lebray P , Fedchuk L , et al. ; LIDO Study Group . Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases . Clin Gastroenterol Hepatol 2015. ; 13 ( 4 ): 763 – 71.e1, 6 .</Citation><ArticleIdList><ArticleId IdType="pubmed">25086193</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson PF , Petrie A . Method agreement analysis: a review of correct methodology . Theriogenology 2010. ; 73 ( 9 ): 1167 – 1179 .</Citation><ArticleIdList><ArticleId IdType="pubmed">20138353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gherlan GS , Calistru PI , Lazar S , Neata M . Transient Elastography (Fibroscan®): The Normal Variability Between Two Measurements . J Hepatol 2012. ; 56 ( S2 ): S413 .</Citation></Reference><Reference><Citation>Ferraioli G , De Silvestri A , Lissandrin R , et al. . Evaluation of Inter-System Variability in Liver Stiffness Measurements . Ultraschall Med 2019. ; 40 ( 1 ): 64 – 75 .</Citation><ArticleIdList><ArticleId IdType="pubmed">29566420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassinotto C , Anselme S , Jacq T , et al. . Inter-platform Variability of Liver Elastography: Pairwise Comparisons of Four Devices . Ultrasound Med Biol 2022. ; 48 ( 11 ): 2258 – 2266 .</Citation><ArticleIdList><ArticleId IdType="pubmed">36050230</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr RG , Wilson SR , Rubens D , Garcia-Tsao G , Ferraioli G . Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement . Radiology 2020. ; 296 ( 2 ): 263 – 274 .</Citation><ArticleIdList><ArticleId IdType="pubmed">32515681</ArticleId></ArticleIdList></Reference><Reference><Citation>Perazzo H , Veloso VG , Grinsztejn B , Hyde C , Castro R . Factors That Could Impact on Liver Fibrosis Staging by Transient Elastography . Int J Hepatol 2015. ; 2015 : 624596 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684863</ArticleId><ArticleId IdType="pubmed">26770833</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>